Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinical Data to acquire Avalon Pharmaceuticals
Additionally, as part of the merger, Clinical Data will issue contingent value rights to Avalon stockholders, payable for up to $2.5 million of additional shares of Clinical Data’s
Additionally, as part of the merger, Clinical Data will issue contingent value rights to Avalon stockholders, payable for up to $2.5 million of additional shares of Clinical Data’s
Patented through 2018, Centany represents an important step in Medimetriks’ plan to commercialize patent-protected therapies for the dermatology and podiatry markets that offer important patient benefits. Medimetriks plans
The new patent covers several new chemical entities, including composition of matter and use of the company’s lead product candidate, OT-551. With anticipated patent life extensions, the patent
The product is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta blockers. Hi-Tech plans
The Phase IIb trial is being conducted at the Friedrich Alexander University Hospital in Erlangen, Germany, led by Eckhart Kampgen, associate professor for strategies of cellular immunotherapy at
The agreement includes syringe pumps and ambulatory pumps, including the new CADD-Solis system. Previously, Smiths Medical had agreements in place with University HealthSystem Consortium (UHC) of Oakbrook, Illinois.
Total value of the contracts for Galapagos is $1 million over 1.5 years. Galapagos’s service division, BioFocus DPI, will develop a high throughput screening assay in mouse neurons
Under the terms of the restructure, CSL will now take full control of the program, including development and commercialization of any potential drugs arising from the program. In
The Committee for Medicinal Products for Human Use’s (CHMP’s) positive opinion is based on data from the AZA-001 trial, which has demonstrated an overall survival benefit for higher-risk
The price to be paid of E48 million will be funded from existing liquidity. The closing of the transaction, expected to take place before the end of 2008,